Tigecycline's Common Side Effects
Tigecycline, a glycylcycline antibiotic used for complicated skin infections, intra-abdominal infections, and community-acquired pneumonia, causes nausea in 20-30% of patients and vomiting in 15-20%. Diarrhea occurs in about 15%, with elevated liver enzymes (ALT/AST) in 10-15%. It's associated with a higher mortality risk (4% vs 2.5% placebo in meta-analyses), mainly from infections, leading to FDA warnings.[1][2]
How Tigecycline Compares to Carbapenems (e.g., Imipenem, Meropenem)
Carbapenems cause less nausea (10-15%) and vomiting (5-10%) than tigecycline. Diarrhea rates are similar (10-20%), but carbapenems have higher risks of seizures (0.5-1%) and C. difficile infections. Tigecycline shows more hepatotoxicity; carbapenems more injection-site reactions. In trials for intra-abdominal infections, tigecycline had similar cure rates but more GI issues.[1][3]
Comparison with Beta-Lactams (e.g., Piperacillin-Tazobactam, Cefepime)
Beta-lactams produce milder GI effects: nausea under 10%, diarrhea 5-15%. They carry higher allergy risks (1-5%) and less frequent liver enzyme elevations (5%). Tigecycline edges out in tolerability for allergy-prone patients but trails in GI comfort. Head-to-head studies for skin infections show tigecycline noninferior in efficacy, with more discontinuations due to nausea.[2][4]
Vs Fluoroquinolones (e.g., Ciprofloxacin, Levofloxacin)
Fluoroquinolones have low nausea (5-10%) but higher tendon rupture (0.1-1%), QT prolongation, and neuropathy risks. Tigecycline avoids these but amplifies GI intolerance. For pneumonia, fluoroquinolones show better overall tolerability in meta-analyses, though tigecycline covers more resistant strains.[1][5]
Vs Vancomycin and Daptomycin for MRSA/Gram-Positives
Vancomycin causes nephrotoxicity (5-15%) and red man syndrome; daptomycin elevates CK (muscle damage, 5-10%) and has eosinophilic pneumonia risks. Tigecycline has negligible kidney or muscle effects but worse GI profile and mortality signal. It's preferred for polymicrobial infections but less so for bacteremia due to lower blood levels.[2][3]
Key Risks and Patient Concerns
Tigecycline's GI effects often lead to 5-10% discontinuation rates, higher than most comparators. Its black-box warning for mortality stems from trials vs comparators like levofloxacin or imipenem. Superinfections (e.g., candidiasis) occur more frequently. Patients report nausea as most disruptive; it's avoided in pregnancy (Category D).[1][2]
[1]: FDA Label - Tygacil (tigecycline), https://www.accessdata.fda.gov/drugsatfdadocs/label/2010/021821s021lbl.pdf
[2]: Tasina E et al., Meta-analysis: Tigecycline mortality risk, Clin Infect Dis (2011), https://academic.oup.com/cid/article/52/8/975/320667
[3]: FDA Advisory - Tigecycline mortality, https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/tigecycline-marketed-tygacil-information
[4]: Corey GR et al., Tigecycline vs vancomycin in skin infections, Clin Infect Dis (2007), https://academic.oup.com/cid/article/44/Supplement2/S105/384950
[5]: Cai Y et al., Tigecycline vs comparators meta-analysis, Antimicrob Agents Chemother (2010), https://aac.asm.org/content/54/5/1891